Hannah Clarke

Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

ACOU085 will be administered in 1 ear, with a matching placebo injection in the respective contralateral middle ear.

The freedom from re-intervention rate was 71%.

Use of focal therapy was shown to prolong the duration of active surveillance.

"I’m hopeful because women in urology are no longer an exception—they’re becoming the norm," says Shaya Taghechian, MD.

The phase 3 RC48-C016 trial met its primary end points.

The data are to be presented at an upcoming medical conference.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

Patient-reported pain scores were significantly improved with stent omission.

“We do not feel that our results undermine the importance of fluid intake for stone prevention," says Alana C. Desai, MD.

Data showed that physical function and self-reported frailty assessments were poorly correlated.

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

Initial study results may be available as soon as the first half of 2026.

Hear from 5 experts as they recap some of the top data from this year's AUA.

Take a look through some of the notable studies that were spotlighted during this year’s meeting.

The sBLA for NAI was submitted to the FDA in March 2025.

These results are expected to support submission of the Hugo system to the FDA for use in urologic procedures.

Data showed an overall CR rate of 82.4%.

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Twelve-month physical functioning scores were comparable between the radical cystectomy arm and the bladder-sparing therapy arm.

A recap of the FDA submissions and regulatory decisions in urology from April 2025.

Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.

The RAPID-III trial will assess outcomes with flexible cystoscopy with or without the FloStent implant deployed.

"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.

Data from the SOUND trial are intended to support submission for FDA 510(k) clearance of the Break Wave device.

View slated interviews with experts as well as insights from urologists on what to watch for.

"In this large study of over 1500 men with an elevated PSA, we found that a low IsoPSA is incredibly reassuring,” says Christopher J. Weight, MD.

Take a look through several of the notable phase 3 trials in progress that will be spotlighted at AUA 2025.